Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

32.76USD
24 Mar 2017
Change (% chg)

$0.03 (+0.09%)
Prev Close
$32.73
Open
$32.71
Day's High
$32.85
Day's Low
$32.34
Volume
1,064,398
Avg. Vol
2,103,746
52-wk High
$58.15
52-wk Low
$31.91

Select another date:

Thu, Mar 23 2017

Teva Pharm says media reports of up to 6,000 layoffs incorrect

JERUSALEM Teva Pharmaceutical Industries' plans to end unprofitable activities and freeze recruitment, but said Israeli media reports of up to 6,000 layoffs were incorrect.

Teva Pharm says media reports of up to 6,000 layoffs incorrect

JERUSALEM Teva Pharmaceutical Industries' plans to end unprofitable activities and freeze recruitment, but said Israeli media reports of up to 6,000 layoffs were incorrect.

UPDATE 1-Teva Pharm says media reports of up to 6,000 layoffs incorrect

JERUSALEM, March 23 Teva Pharmaceutical Industries' plans to end unprofitable activities and freeze recruitment, but said Israeli media reports of up to 6,000 layoffs were incorrect.

Teva Pharm may fire 6,000 workers -Israeli media report

JERUSALEM, March 23 Teva Pharmaceutical Industries may fire as many as 6,000 workers worldwide as part of a multi-year efficiency plan, Israel's Calcalist news website reported on Thursday.

BRIEF-OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico

* OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico

Teva Pharm sells shares in Gamida Cell, raises stake in Clal Biotech

* Teva Pharmaceutical Industries has agreed to sell a small stake in Israel-based Gamida Cell and in return will increase its holdings in Clal Biotechnology, the companies said on Sunday.

BRIEF-Teva says FDA granted priority review for SD-809 for treatment of tardive dyskinesia

* Teva Pharmaceutical Industries Ltd - FDA has assigned a prescription drug user fee act (PDUFA) goal date of August 30, 2017.

Teva settles 'vast majority' of lawsuits over generic Reglan

Teva Pharmaceutical Industries Ltd has agreed to settle the "vast majority" of the roughly 4,000 lawsuits it faced over its generic version of the heartburn drug Reglan, which has been linked to a serious neurological disorder.

BRIEF-Teva said to weigh options for branded generics to reduce debt- Bloomberg, citing sources

* Teva said to weigh options for branded generics to reduce debt - Bloomberg, citing sources

Teva seeks CEO with pharma background to lead recovery efforts

TEL AVIV Teva Pharmaceutical Industries is seeking a new chief executive with deep drug industry experience, the Israel-based company said on Monday as it looks to restore confidence after a series of missteps and the departure of CEO Erez Vigodman.

Select another date:

More From Around the Web